For breast cancer with PIK3CA mutations and urothelial cancer with FGFR3 translocations/mutations, the Food and Drug Administration (FDA) has approved phosphoinositide 3-kinases (PI3K) and fibroblast growth factor receptor (FGFR) inhibitors, respectively, for clinical use [42,43]. Here, PIK3CA is linked to breast cancer.